ArticlePloS one2026
Significance of RGS13 expression in lupus B cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesB cells play important roles in systemic lupus erythematosus (SLE) pathogenesis. In this study, we explored the proteins preferentially expressed in SLE B cells, especially double-negative 2 B (DN2B) and age-associated B cells (ABCs), and analysed their functions.
methodsWe used our previously reported dataset to identify the mRNAs preferentially expressed in SLE B cells and confirmed their expression in each B cell subset via flow cytometry. Additionally, we also used knockout mice of the identified gene to investigate its roles.
resultsOf the 525 mRNAs exclusively upregulated in SLE B cells, regulator of G protein signalling (RGS)-13 was identified as a top-ten gene of interest. Its expression levels were determined via quantitative polymerase chain reaction and correlated with the anti-dsDNA antibody levels. Flow cytometry revealed that RGS13 levels were particularly high in DN2B cells. Among the DN2B cell differentiation-inducing factors, B cell receptor stimulation induced RGS13 expression. Total B cell, follicular B cell, and ABC numbers were reduced in the spleen, whereas the number of germinal centre B cells, which also highly express Rgs13, was unaffected in Rgs13-/- mice. Moreover, total B cell number increased in the bone marrow but remained unchanged in the peripheral blood in Rgs13-/- mice. No difference in responsiveness to ABC-inducing stimuli was observed between the Rgs13-/- and wild-type mice.
conclusionOverall, RGS13 was highly expressed in lupus DN2B cells and mouse ABCs, induced by B cell receptor stimulation, and indirectly associated with the differentiation and maintenance of ABCs relevant to autoimmunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.